TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Author:
Funder
LOXO Oncology
Bayer Corporation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Link
http://link.springer.com/article/10.1007/s11523-018-0590-1/fulltext.html
Reference90 articles.
1. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B. 2006;361:1545–64.
2. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319:743–8.
3. McGregor LM, Baylin SB, Griffin CA, Hawkins AL, Nelkin BD. Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal assignment, and evidence for a splice variant. Genomics. 1994;22:267–72.
4. Nakagawara A, Liu XG, Ikegaki N, White PS, Yamashiro DJ, Nycum LM, et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics. 1995;25:538–46.
5. Valent A, Danglot G, Bernheim A. Mapping of the tyrosine kinase receptors trkA (NTRK1), trkB (NTRK2) and trkC(NTRK3) to human chromosomes 1q22, 9q22 and 15q25 by fluorescence in situ hybridization. Eur J Hum Genet. 1997;5:102–4.
Cited by 78 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Insights in Molecular Therapies for Hepatocellular Carcinoma;Cancers;2024-05-10
2. Novel therapeutic strategies for rare mutations in non-small cell lung cancer;Scientific Reports;2024-05-05
3. Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology;JCO Precision Oncology;2024-05
4. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26
5. NTRK3 exhibits a pro‐oncogenic function in upper tract urothelial carcinomas;The Kaohsiung Journal of Medical Sciences;2024-04-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3